Advances in stroke prevention in atrial fibrillation: Enhanced risk stratification combined with the newer oral anticoagulants

Clinical Cardiology

Volumn 36, Issue 6, 2013, Pages 312-322

  Verheugt, Freek W A ^a  

^a Onze Lieve Vrouwe Gasthuis ^*  (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; CLOPIDOGREL; DABIGATRAN; EDOXABAN; IRBESARTAN; QUINIDINE; RIVAROXABAN; THROMBIN; VERAPAMIL; WARFARIN;

ANTICOAGULANT THERAPY; ANTICOAGULATION; AORTA ATHEROSCLEROSIS; ARTERIAL THROMBOEMBOLISM; BLEEDING; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL DECISION MAKING; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG USE; DYSPEPSIA; EMBOLISM; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; HYPERTENSION; INTERNATIONAL NORMALIZED RATIO; MEDICAL HISTORY; PATIENT MONITORING; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIMARY PREVENTION; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SCORING SYSTEM; SECONDARY PREVENTION; SEX; THROMBOSIS PREVENTION; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME; VASCULAR DISEASE;

ADMINISTRATION, ORAL; AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; DECISION SUPPORT TECHNIQUES; FEMALE; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; PATIENT SELECTION; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; RISK FACTORS; STROKE; TREATMENT OUTCOME;

EID: 84879088955     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.22122     Document Type: Review

References (48)

1. Fuster V, Ryden LE, Cannom DS, et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011; 123: e269-e367.
2. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001; 285: 2370-2375.
3. Miyasaka Y, Barnes ME, Gersh BJ, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006; 114: 119-125.
4. Wolf PA, Abbott RD, Kannel WB,. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991; 22: 983-988.
5. Hughes M, Lip GYH,. Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data. Thromb Haemost. 2008; 99: 295-304.
6. Stroke Risk in Atrial Fibrillation Working Group. Independent predictors of stroke in patients with atrial fibrillation: a systematic review. Neurology. 2007; 69: 546-554.
7. Singer DE, Albers GW, Dalen JE, et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008; 133: 546S-592S.
8. Camm AJ, Lip GYH, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012; 14: 1385-1413.
9. Hart RG, Pearce LA, Aguilar MI,. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007; 146: 857-867.
10. Olesen JB, Lip GYH, Lindhardsen J, et al. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: a net clinical benefit analysis using a "real world" nationwide cohort study. Thromb Haemost. 2011; 106: 739-749.
11. Lip GYH, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor based approach: The Euro Heart Survey on Atrial Fibrillation. Chest. 2010; 137: 263-272.
12. Nieuwlaat R, Capucci A, Lip GYH, et al. Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation. Eur Heart J. 2006; 27: 3018-3026.
13. van Staa TP, Setakis E, Di Tanna GL, et al. A comparison of risk stratification schemes for stroke in 79,884 atrial fibrillation patients in general practice. J Thromb Haemost. 2011; 9: 39-48.
14. Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001; 285: 2864-2870.
15. Gage BF, van Walraven C, Pearce L, et al. Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. Circulation. 2004; 110: 2287-2292.
16. You JJ, Singer DE, Howard PA, et al. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012; 141: e531S-e575S.
17. Olesen JB, Lip GYH, Hansen ML, et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ. 2011; 342: d124.
18. Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010; 138: 1093-1100.
19. Gallego P, Roldan V, Torregrosa JM, et al. Relation of the HAS-BLED bleeding risk score to major bleeding, cardiovascular events and mortality in anticoagulated patients with atrial fibrillation. Circ Arrhythm Electrophysiol. 2012; 5: 312-318.
20. Lip GYH, Frison L, Halperin JL, et al. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. J Am Coll Cardiol. 2011; 57: 173-180.
21. ACTIVE Writing Group of the ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet. 2006; 367: 1903-1912.
22. Wann LS, Curtis AB, January CT, et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011; 123: 104-123.
23. Lin PJ,. Reviewing the reality: why we need to change. Eur Heart J Suppl. 2005;7(Suppl E): E15-E20.
24. Self TH, Reaves AB, Oliphant CS, et al. Does heart failure exacerbation increase response to warfarin? A critical review of the literature. Curr Med Res Opin. 2006; 22: 2089-2094.
25. Shetty HG, Fennerty AG, Routledge PA,. Clinical pharmacokinetic considerations in the control of oral anticoagulant therapy. Clin Pharmacokinet. 1989; 16: 238-253.
26. Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008; 133: 160S-198S.
27. Ansell J, Hollowell J, Pengo V, et al. Descriptive analysis of the process and quality of oral anticoagulation management in real-life practice in patients with chronic non-valvular atrial fibrillation: the International Study of Anticoagulation Management (ISAM). J Thromb Thrombolysis. 2007; 23: 83-91.
28. Ogilvie IM, Newton N, Welner SA, et al. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med. 2010; 123: 638-645.
29. Nieuwlaat R, Capucci A, Camm AJ, et al. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J. 2005; 26: 2422-2434.
30. Nieuwlaat R, Olsson SB, Lip GYH, et al. Guideline-adherent antithrombotic treatment is associated with improved outcomes compared with undertreatment in high-risk patients with atrial fibrillation. The Euro Heart Survey on Atrial Fibrillation. Am Heart J. 2007; 153: 1006-1012.
31. Waldo AL, Becker RC, Tapson VF, et al. Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation. J Am Coll Cardiol. 2005; 46: 1729-1736.
32. Deplanque D, Leys D, Parnetti L, et al. Stroke prevention and atrial fibrillation: reasons leading to an inappropriate management. Main results of the SAFE II study. Br J Clin Pharmacol. 2004; 57: 798-806.
33. Testai FD, Gorelick PB,. New approaches to stroke prevention in atrial fibrillation. Curr Treat Options Cardiovasc Med. 2010; 12: 261-273.
34. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361: 1139-1151.
35. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Newly identified events in the RE-LY trial. N Engl J Med. 2010; 363: 1875-1876.
36. Hohnloser SH, Oldgren J, Yang S, et al. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial. Circulation. 2012; 125: 669-676.
37. Uchino K, Hernandez AV,. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch Intern Med. 2012; 172: 397-402.
38. Eikelboom JW, Wallentin L, Connolly SJ, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation. 2011; 123: 2363-2372.
39. Boehringer Ingelheim. Breakthrough therapy PRADAXA (dabigatran etexilate) first drug in 50 years to gain approval for stroke prevention in atrial fibrillation in EU. 2011. http://www.boehringer-ingelheim.com/news/news- releases/press-releases/2011/04-aug-2011-dabigatranetexilate.html. Accessed November 7, 2011.
40. Medpage Today. Dabigatran: the case of the missing 110-mg dose. 2010. http://www.medpagetoday.com/Cardiology/Arrhythmias/22906. Accessed July 26, 2012.
41. Heartwire press release. FDA investigating serious bleeding events with dabigatran. 2011. http://www.theheart.org/article/1324923.do. Accessed February 15, 2012.
42. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365: 883-891.
43. Hankey GJ, Stevens S, Piccini JP, et al. Predictors of intracranial hemorrhage among anticoagulated patients with atrial fibrillation: insights from the rivaroxaban once-daily oral direct Factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF). Stroke. 2012; 43: A152.
44. Halperin JL, Wojdyla D, Piccini JP, et al. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the ROCKET-AF trial. Stroke. 2012; 43: A148.
45. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365: 981-992.
46. Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011; 364: 806-817.
47. Pfizer Web site. Eliquis (apixaban) approved in Europe for prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. 2012. http://www.pfizer.com/news/press-releases/pfizer-press-release.jsp?guid= 2664. Accessed November 27, 2012.
48. Ruff CT, Giugliano RP, Antman EM, et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). Am Heart J. 2010; 160: 635-641.